Samir N. Khleif

Best Publications

• Cancer classification using the Immunoscore: a worldwide task force

  Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  961
  Citations

• PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

  Vivek Verma;Vivek Verma;Rajeev K Shrimali;Rajeev K Shrimali;Shamim Ahmad;Winjie Dai

  319
  Citations

• Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

  Dmitriy Zamarin;Robert A. Burger;Michael W. Sill;Daniel J. Powell

  316
  Citations

• Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?

  Sandra Demaria;Chandan Guha;Jonathan Schoenfeld;Zachary Morris

  268
  Citations

• Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

  Sacha Gnjatic;Vincenzo Bronte;Laura Rosa Brunet;Marcus O. Butler

  249
  Citations

• Future perspectives in melanoma research

  Paolo A. Ascierto;Sanjiv Agarwala;Gerardo Botti;Alessandra Cesano

  246
  Citations

• Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation

  Unknown

  203
  Citations

• Defining the critical hurdles in cancer immunotherapy

  Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  190
  Citations

• Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  Asha Nayak-Kapoor;Zhonglin Hao;Ramses Sadek;Robin Dobbins

  173
  Citations

• A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

  S N Khleif;S I Abrams;J M Hamilton;E Bergmann-Leitner

  169
  Citations

• MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.

  Vivek Verma;Vivek Verma;Nazli Jafarzadeh;Shannon Boi;Subhadip Kundu

  169
  Citations

• Mutant KRAS conversion of conventional T cells into regulatory T cells

  Stephanie Zdanov;Magis Mandapathil;Rasha Abu Eid;Saudat Adamson-Fadeyi

  166
  Citations

• Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

  Rajeev Kumar Shrimali;Shamim Ahmad;Vivek Verma;Peng Zeng

  166
  Citations

• Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

  Rasha Abu-Eid;Raed N. Samara;Laurent Ozbun;Maher Y. Abdalla

  163
  Citations

• A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.

  Jose Lutzky;Scott Joseph Antonia;Andy Blake-Haskins;Xia Li

  146
  Citations

• Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms

  Unknown

  144
  Citations

• Clinical trial designs for the early clinical development of therapeutic cancer vaccines

  Richard M. Simon;Seth M. Steinberg;Michael Hamilton;Allan Hildesheim

  144
  Citations

• Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.

  Antoun Toubaji;Moujahed Achtar;Maurizio Provenzano;Vincent E. Herrin

  141
  Citations

• Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

  Alessandro D. Santin;Wei Deng;Michael Frumovitz;Natalia Buza

  138
  Citations

• A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

  Osama E. Rahma;Ed Ashtar;Malgorzata Czystowska;Marta E. Szajnik

  132
  Citations